ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Argus™ II Retinal Stimulation System Feasibility Protocol

This study is currently recruiting participants.
Verified by Second Sight Medical Products, July 2007

Sponsors and Collaborators: Second Sight Medical Products
National Institutes of Health (NIH)
Information provided by: Second Sight Medical Products
ClinicalTrials.gov Identifier: NCT00407602
  Purpose

The objective of this feasibility study is to evaluate the safety and utility of the Argus II Retinal Stimulation System in providing visual function to blind subjects with severe to profound retinitis pigmentosa.


Condition Intervention Phase
Retinitis Pigmentosa
Device: Argus II Retinal Stimulation System
Phase II

Genetics Home Reference related topics:   Lenz microphthalmia syndrome    oculofaciocardiodental syndrome    Peters plus syndrome    X-linked juvenile retinoschisis   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Official Title:   Argus™ II Retinal Stimulation System Feasibility Protocol

Further study details as provided by Second Sight Medical Products:

Primary Outcome Measures:
  • Visual acuity
  • Safety

Secondary Outcome Measures:
  • Activities of daily living
  • Quality of life
  • Mobility

Estimated Enrollment:   10

  Eligibility
Ages Eligible for Study:   50 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

Inclusion Criteria:

  • A confirmed history of retinitis pigmentosa (outer retinal degeneration - France only) with remaining visual acuity of bare light perception (2.3 logMAR - France only) or worse in both eyes.
  • Functional ganglion cells and optic nerve as determined by a measurable electrically evoked response or documented light perception.
  • A history of former useful form vision in the worse-seeing eye.
  • Must be fifty (50) (eighteen (18) - France only) years or older at the time of enrollment.
  • Must reside within two (2) hours distance (by ground transportation) of the investigational site.
  • Must be willing and able to comply with the protocol testing and follow-up requirements.

Exclusion Criteria:

  • Optic Nerve disease

    • History of glaucoma
    • Optic neuropathy or other confirmed damage to optic nerve or visual cortex damage
  • Diseases or conditions that effect retinal function including but not limited to:

    • Central retinal artery/vein occlusion (CRAO or CRVO)
    • End-stage diabetic retinopathy
    • Retinal detachment or history of retinal detachment
    • Trauma
    • Infectious or inflammatory retinal diseases
  • Diseases or conditions that prevent adequate visualization of the retina including, but not limited to corneal degeneration that cannot be resolved before implant.
  • Diseases or conditions of the anterior segment that prevent the ability to adequately perform the physical examination including but not limited to trauma or lid malpositions.
  • Diseases of the ocular surface including but not limited to keratitis sicca.
  • An ocular condition that predisposes the subject to eye rubbing.
  • Any disease or condition that prevents understanding or communication of informed consent, study demands, and testing protocols, including:

    • Neurologic disease including diagnosed forms of dementia and/or progressive neurologic disease
    • Psychiatric Disease including diagnosed forms of depression
    • Non-English speaking including American Sign language
    • Deafness
  • Pregnancy
  • Subject has another active implantable device (e.g. cochlear implant), or any form of metallic implant in the head
  • Subjects with a history of tobacco use greater than twenty pack-years.
  • Subject is participating in another investigational drug or device study that may conflict with the objectives, follow-up or testing of this study
  • Any health concern that makes general anesthesia inadvisable.
  • Subject has unrealistic expectations of the implant.
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00407602

Locations
United States, California
Doheny Eye Institute     Active, not recruiting
      Los Angeles, California, United States, 90033
University of California San Francisco     Active, not recruiting
      San Francisco, California, United States, 94143
United States, Maryland
Johns Hopkins, Wilmer Eye Institute     Active, not recruiting
      Baltimore, Maryland, United States, 21205
United States, New York
Columbia University, Department of Ophthalmology, Edward S. Harkness Eye Institute     Active, not recruiting
      New York, New York, United States, 10032
United States, Texas
Retina Foundation of the Southwest     Active, not recruiting
      Dallas, Texas, United States, 75231
France
Centre d'Investigation Clinique, Service d'Ophtalmologie, Quinze-Vingts National Eye Hospital, 28 rue de Charenton, 75557 Cedex 12     Recruiting
      Paris, France
      Contact: Saddek Mohand-Said, MD     +33 1 40 02 14 31     mohand@quinze-vingts.fr    
      Contact: Jeanne Haidar     +33 1 40 02 14 57     jhaidar@cicoph.org    
      Principal Investigator: Jose Sahel, MD            
      Sub-Investigator: Saddek Mohand Said, MD            
Mexico, Jalisco
Puerta de Hierro, Centro Medico, Centro de Retina     Recruiting
      Zapopan, Jalisco, Mexico, 51116
      Contact: Arturo Santos Garcia, MD     +52 (33) 3848-5468        
      Principal Investigator: Arturo Santos Garcia, MD            
      Sub-Investigator: Enrique Roig Melo-Granados, MD            
Switzerland
Clinique d'Ophthalmologie Hopitaux, Universitaires de Geneve 22 rue Alcide Jentzer 1205     Recruiting
      Geneva, Switzerland
      Contact: Joel Salzmann, MD     +41 22 382 84 89     Joel.Salzmann@hcuge.ch    
      Contact: Jorg Sommerhalder     +41 22 382 84 20     jorg.r.sommerhalder@hcuge.ch    
      Principal Investigator: Avinoam Safran, MD            
      Sub-Investigator: Joel Salzmann, MD            
      Sub-Investigator: Marco Pelizzone, PhD.            
      Sub-Investigator: Jorg Sommerhalder, PhD            
      Sub-Investigator: Angelica P Perez Fornos, PhD            
United Kingdom
Moorfields Eye Hospital, Vitreoretinal Research Unit     Recruiting
      City Road, London, United Kingdom, EC1V 2PD
      Contact: Lyndon daCruz, M.D.     +44 (0)20 7566 2251     Lyndon.daCruz@moorfields.nhs.uk    
      Contact: Andrew Webster, MD     +44 0(20) 7566 2255     Andrew.webster@ucl.ac.uk    
      Principal Investigator: Lyndon daCruz, MD            
      Sub-Investigator: Andrew Webster, MD            

Sponsors and Collaborators
Second Sight Medical Products
National Institutes of Health (NIH)
  More Information


Study ID Numbers:   CP-003-001
First Received:   December 1, 2006
Last Updated:   August 28, 2008
ClinicalTrials.gov Identifier:   NCT00407602
Health Authority:   United States: Food and Drug Administration

Keywords provided by Second Sight Medical Products:
retinitis pigmentosa  
device  
retinal implant  
retinal prosthesis  
RP  

Study placed in the following topic categories:
Pigmentary retinopathy
Genetic Diseases, Inborn
Eye Diseases
Cone rod dystrophy
Retinitis Pigmentosa
Retinitis
Retinal Degeneration
Eye Diseases, Hereditary
Retinal Diseases
Retinal degeneration

ClinicalTrials.gov processed this record on October 17, 2008




Links to all studies - primarily for crawlers